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Background. Exhaled nitric oxide (FeNO) has been reported to be elevated in the oxidative stress involved in asthmatic patients,
and the reaction of nitric oxide (NO) with superoxide anions results in the formation of nitrotyrosine. The purpose of this study
was to investigate the eﬀect of inhaled steroid treatment on nitrotyrosine levels collected by exhaled breath condensate (EBC)
and on FeNO. Methods. This was a single-blind placebo-controlled study. The lung function, FeNO, and nitrotyrosine levels were
evaluated in 10 asthmatic children. Results. The nitrotyrosine levels were stable during the placebo period (T0 = 1.16ng/ml versus
T1 = 1.05ng/ml; NS.), whereas they decreased after the treatment with ﬂunisolide (T2 = 1.14ng/ml versus T3 = 0.88ng/ml;
P<. 001). No signiﬁcant reduction in FeNO levels was observed after placebo treatment (T0 = 38.4ppbversusT1= 34.7ppb,
NS.). In contrast, FeNO values decreased signiﬁcantly being at T3 = 14.9ppb(T1versusT3;P = .024). Conclusions. This study
shows that corticosteroid treatment reduces nitrotyrosine levels in EBC of asthmatic subjects.
Copyright © 2006 A. Bodini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Oxidative stress is implicated in airway inﬂammatory dis-
ease such as asthma, chronic obstructive pulmonary dis-
ease (COPD), and cystic ﬁbrosis (CF) [1]. Diﬀerent types
of airway inﬂammatory cells, especially eosinophils, produce
more superoxide anions (O2
−) and release reactive nitro-
gen/oxygen compounds such as NO [2]. The reaction of NO
and superoxide anions (O2
−) in the airway results in the for-
mation of peroxynitrite, a highly reaction oxidative species,
which can nitrate the tyrosine residues of proteins to form
thestableproductofnitrotyrosine[3].Theformationofper-
oxynitrite is now well established in a variety of airway dis-
eases [2, 3], and it has been demonstrated to be capable to
damage pulmonary epithelial cells [4] and to induce airway
hyperresponsiveness [5].
Exhaled NO and a large number of molecules collected
by EBC have been demonstrated to be increased in the air-
wayofasthmaticpatients[6],andtheyarenowestablishedto
represent markers of airway inﬂammation [7]. A signiﬁcant
correlation has been demonstrated between the reduction
in FeNO levels and eosinophils markers of inﬂammation in
asthmatic patients treated with inhaled corticosteroids [8]. A
recent study suggests that inhaled steroid treatment resulted
in a signiﬁcant reduction to nitrotyrosine immunoreactivity
in the airway epithelium, lung parenchyma, and inﬂamma-
tory cells of patients with asthma [9].
The purpose of this pilot study was to investigate the ef-
fect of inhaled steroid treatment on nitrotyrosine levels, in
comparison with pulmonary function and airway inﬂamma-




a history of mild-to-moderate bronchial asthma, according
to the American Thoracic Society (ATS) deﬁnition [10]a n d
positiveskinprickteststohousedustmite(HDM)wereeval-
uated. All children were recruited at the Department of Pae-
diatrics, University of Verona, Verona, Italy. None of the pa-
tients had respiratory infections for at least two months be-
fore the beginning of the study and none of the children had
received oral corticosteroids for at least two months before
and after admission to the study.
The children did not present any clinically evident asth-
maexacerbation.ThestudywasapprovedbytheLocalEthics
Committee and both children and their parents gave in-
formed consent.2 Mediators of Inﬂammation
Thiswasasingle-blindplacebo-controlledpilotstudy.All
asthmatic children received placebo for 8 weeks (T0-T1) and
then after a washout of 8 weeks (T1-T2), inhaled ﬂunisolide
(Lunibron A, Valeas SpA, Milano, Italy; 800mcg/dose) for
further 8 weeks (T2-T3). A ﬁnal washout period of further 8
weeks without any treatment concluded the study (T3-T4).
During the study period the symptoms were recorded
daily. Treatments were administered by the same model or
pneumatic nebulizer (BimboNeb, Markos Mefar SpA, Bres-
cia, Italy), which was provided to all of the patients.
Inhaled β2 agonists were allowed to be used as needed.
Neither cromons nor inhaled steroids, other than ﬂunisolide
administered according to the experimental design, were al-
lowed for the time of the study. None of the children received
oral steroid after admission to the study.
The evaluations at T0, T1, T2, T3, and T4 consisted in
lung function assessment, measurement of FeNO, and col-
lection of EBC.
EBCcollectionandmeasurement
EBC samples were collected by a condensing device formed
by two glass chambers (Incofar Srl, Modena, Italy) [11]. The
inner glass chamber was cooled by means of ice and sus-
pended in a larger glass chamber. The children were in-
structed to tidally breathe by the mouth through a two-way
nonrebreathing valve for 15min. To minimize salivary con-
tamination the two-way valve served as a saliva trap, with a
12cm banded tube vertically positioned between the mouth-
piece and the condenser while the mouth of the subject re-
mained at a lower position with respect to the inlet of the de-
vice. Children were asked to periodically swallow their saliva.
E B Cs a m p l e sw h e r es t o r e di ns t e r i l et u b e sa t−70◦C.
Nitrotyrosine levels were measured by speciﬁc enzyme
immunoassay (EIA) kits (BIOXYTECH Nitrotyrosine—EIA;
Oxis Research, Portland, Ore, USA) whose validity in EBC
was shown by Hanazawa et al [2].
LungfunctionandFeNOmeasurement
Lung function was measured by a Vitalograph Compact
spirometer (Vitalograph Ltd, Buckingham, UK); FEV1 and
FEF25–75 were considered in the analysis of the results. The
best value of three manoeuvres was accepted and expressed
as percentage of the predicted normal values, according to
ATS Guidelines [12].
FeNO was measured by chemiluminescence analyzer
NIOX system (Aerocrine, Stockolm, Sweden), using a single-
breath online method according to ERS/ATS Guidelines for
FeNO measurement in children [13]. Children inhaled NO-
free air and exhaled through a dynamic ﬂow restrictor with a
target ﬂow of 50mL/s for at least 6-7s.
Statisticalanalysis
The data were expressed as means ± standard error of the



























Figure 1: Individual data points of FeNO levels at the times of the
study (T0, T1, T2, T3, and T4). Marked short lines represent mean
values.
bution for all the investigated parameters in our study pop-
ulation. Diﬀerences between the times of the study (T0, T1,
T2, T3, and T4) were performed by analysis of variance (one
way RM ANOVA) and multiple comparison procedures by
Bonferroni’s correction. Correlations were evaluated by sim-
ple regression test. A P value of <. 05 was considered signiﬁ-
cant.
RESULTS
Two children presented an upper respiratory tract infection
and they did not complete the study. These two subjects were
excluded from the ﬁnal analysis; therefore, 8 subjects com-
pleted the study and were considered in the ﬁnal analysis. No
adverse event was observed during the study period.
FeNO
Exhaled nitric oxide was measured in all asthmatic children.
No signiﬁcant reduction was observed in FeNO levels after
the 8 weeks of placebo treatment (T0 = 38.4ppb± 4.53 ver-
sus T1 = 34.7ppb± 5.35, NS; 95% conﬁdence interval CI,
27,6–49,1; P = .05) and after the ﬁrst washout period (T1
= 34.7ppb± 5.35 versus T2 = 42.6ppb± 10, NS; 95% CI,
22–47,3; P = .05). In contrast, FeNO values decreased signif-
icantly being at T3 = 14.9ppb±3.38 (T1 versus T3 P = .024;
T2 versus T3 P<. 001; 95% CI, 18,7–66; P = .05). After the
second washout period (T4) there was a signiﬁcant increase
in FeNO levels to 45ppb ± 7.31 (T3 versus T4P<. 001; 95%
CI, 6,8–22,8; P = .05) (Figure 1).
Nitrotyrosine
The quantitative determination of nytrotirosine was possi-
ble in the EBC from all the subjects. The levels of nitroty-
rosine in EBC were stable in the study group during the
placebo and ﬁrst washout period (T0 = 1.16ng/mL ± .05,
T1 = 1.05ng/mL ± .03, T2 = 1.14ng/mL ± .03; T0 ver-
sus T1 NS; T1 versus T2 NS), whereas they decreased after
the period of ﬂunisolide treatment (T3 = .88ng/mL ± .04;

































Figure 2: Individual data points of nitrotyrosine levels in EBC at
the times of the study (T0, T1, T2, T3, and T4). Marked short lines
represent mean values.
the nitrotyrosine levels in EBC showed a signiﬁcant increase
(T4 = 1.17ng/mL ± .03; T3 versus T4P<. 001) (Figure 2).
Lungfunction
Allofthechildrenperformedlungfunctiontest.Thedataare
presented in Table 1.
Correlations
NocorrelationwasfoundbetweenFeNOlevels,nitrotyrosine
concentration, and spirometric parameters (FEV1FEF25–75)
in the study group.
DISCUSSION
This was a preliminary study investigating whether nitroty-
rosine in EBC canreﬂectairwayinﬂammation in asthma and
whether it was modulated by treatment with inhaled corti-
costeroids.
The investigating airway inﬂammation was mainly based
on invasive methods until the discovery that exhaled nitric
oxide can be used as surrogate marker of airway inﬂamma-
tion, particularly in childhood asthma [14]. Exhaled NO is
now established as a marker of airway inﬂammation [15],
i th a sb e e nd e m o n s t r a t e dt ob ea b l et op r e d i c tl u n gf u n c -
tion decline and to reﬂect the eﬀect of treatment with anti-
inﬂammatory agents [16] and also the present study shows
a signiﬁcant decrease in FeNO levels when the children were
treated with inhaled ﬂunisolide.
FeNO is, however, a single marker of airway inﬂam-
mation, and therefore for a more comprehensive evalua-
tion of the ongoing processes of inﬂammation in asthma
EBC has been recently proposed [17]. It has recently been
shownthatEBCcollectedfromadultpatientscontainsawide
number of molecules such as leukotrienes, prostaglandins,
albumin and other proteins, such as cytochines [6, 11,
17]. Furthermore, a number of mediators related to NO
pathway, including nitrite as a metabolite of nitric oxide,
nitrotyrosine, nitrosothiols in addition to small molecular
mediators associated with oxidative stress, such as hydrogen
ions andhydrogenperoxide,havebeendetectedinEBCsam-
ples [2, 18].
Nitrotyrosine has been considered to be an indicator of
the involvement of reactive nitrogen species [3] and in the
airway inﬂammatory epithelium of asthma patients there
is a strong immunoreactivity to nitrotyrosine, suggesting a
pathophysiological role for reactive nitrogen species in in-
ﬂammatory lung diseases [19].
Recently a signiﬁcant increase in nitrotyrosine levels in
EBC has been demonstrated in stable CF patients, compared
withnormalsubjects[18].Inaddition,nitrotyrosineconcen-
tration in EBC in mild and untreated asthmatic adults was
f o u n dt ob ec o r r e l a t e dw i t he x h a l e dN Ol e v e l[ 2, 17].
Nevertheless, the results of the present study conﬁrm the
ﬁndings of a recent report by Baraldi et al in asthmatic chil-
dren failing to show any correlation between FeNO and 3-
nitrotyrosine [20].
Furthermore, in the present study, it has been demon-
strated that exhaled nitrotyrosine concentrations in EBC was
decreased after inhaled steroid therapy. These data are in
agreement with the observation of Hanazawa et al [2] sug-
gesting that nitrotyrosine concentrations in EBC were signif-
icantly increased in steroid-untreated asthmatic patients.
The data from EBC samples conﬁrm previous observa-
tionsshowingadirecteﬀectoftreatmentwithinhaledsteroid
on nitrotyrosine-mediated immunoreactivity and NO pro-
duction in airway epithelium of asthmatic adult patients
has previously been demonstrated in samples obtained by
ﬁberoptic bronchial biopsies [9].
In addition, intense nitrotyrosine immunoreactivity was
demonstrated in the airway and parenchyma lung of asthma
patients who died of status asthmaticus despite steroid treat-
ment thus suggesting that status asthmaticus is characterized
by a failure of corticosteroids to control the formation of re-
active nitrogen species [19].
Furthermore, in this study, a signiﬁcant increase in
FEF25–75 values during treatment with nebulized ﬂunisolide
was observed, therefore suggesting an action of this drug
on peripheral airways. These data, indeed, are in agreement
with a recent observation by Bergeron et al who showed that
hydroﬂuoroalkane-ﬂunisolide is associated with a signiﬁcant
decrease in the expression of α-smooth muscle actin in pe-
ripheral airways, which correlated with improvement in pe-
ripheral airway function [21].
This was a pilot study, the main limitation for which was
the small sample size. However, despite the small number
of subjects, the statistical analysis showed highly signiﬁcant
changes in the evaluated parameters for the actively treated
children. If, on the one hand, the small number of subjects
is likely to reduce the external validity of the study, on the
otherhand,thelevelofstatisticalsigniﬁcancereachedinsuch
a small sample size conﬁrms the relevance of changes in the
investigational parameters.
In summary, this pilot study suggests that nitrotyrosine
concentrations, related to FeNO levels, were detectable in
EBC of asthmatic children and were reduced when the chil-
dren received corticosteroids treatment. In addition it also
provided evidence that nebulized ﬂunisolide can have an4 Mediators of Inﬂammation
Table 1: Mean (±SEM) lung function data and p values.
T0 T1 T2 T3 T4
FEV1 (% pred) 86.5 ±2.58
T0 versus T3 P<. 001
90.1 ±2.88
86.4 ±2.92
T2 versus T3 P<. 001
101.3 ±4.81
T3 versus T4 P<. 001 T1 versus T3 P<. 001 84 ±2.75
T1 versus T4 P<. 05
FEF25–75 (% pred) 98.5 ± 7.73 101.1 ±7.46 94.7 ±6.45 121.9 ±8.88 93.5 ±5.13
T0 versus T3 P<. 001 T1 versus T3 P<. 001 T2 versus T3 P<. 001 T3 versus T4 P<. 001
anti-inﬂammatory eﬀect which is accompanied by a recov-
ery of lung function values at the site of peripheral airways.
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